Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
about
Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesAlleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Myelofibrosis: an update on drug therapy in 2016.Myeloproliferative neoplasm stem cells.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Treatment of Myelofibrosis: Old and New Strategies.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceWhich patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.Primary myelofibrosis: current therapeutic options.The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure.Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.Benefits and pitfalls of Peg-Interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis, a French Intergroup of Myeloproliferative neoplasms (FIM) study.Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.Is there consensus on consensus?Recent advances in the diagnosis and management of primary myelofibrosis.Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
P2860
Q28076096-1881A4B2-2D49-4AE0-820A-7339870F7263Q33430113-7C3C165F-D879-4979-8CC5-728FEA47AEE3Q33432285-EBD977BF-E30E-4ABA-925F-767046A1AD80Q33432755-0715C28A-9547-4048-BC85-9F90958006CBQ36308248-D4F147F8-9530-4EB8-AFA5-67C4A076B5B0Q38382105-5F4C67CE-1250-4E2F-9E95-DA1A8B5E8FAFQ38603384-32088D29-3BE5-49E9-98B2-6C686A8BADFDQ38613880-BD74F9BF-93EF-4A99-817F-7FBBFF47E7BAQ38683077-443BF0AD-F95E-4DFE-B744-1A9708ACB9C3Q38684435-9AB4FFB0-8EE3-4597-8B57-E5F3A5E5AA30Q38786380-AC49B034-01F0-42ED-9062-D83F08AA2932Q38984578-E7923F82-6F04-44B4-8FCC-E94C6B2565A1Q38989215-5E2EE6D8-C33E-46CD-A0C8-149C6B19CD7AQ39118859-FBFB15FF-24A7-49C2-83F9-611C15389DB0Q39307476-ABC4A601-A9F6-4E1E-A1B1-1D200525A976Q39349869-B5BA8B37-C18E-42B6-876C-AC72C748AE26Q39554738-95F38D5F-10B6-4E0E-8A81-5DB2A61624C9Q40085126-3B7D4A02-4260-4D1E-BBBB-D793F1BA6DA1Q40094493-1ABB2459-F7E3-4CA7-9816-CAF9EF918DD4Q40261233-6B99141D-553D-4FDD-9F07-911427E47D51Q40829969-ED4A4196-9C9C-426E-B4EB-BA53E4D4BAB3Q41186952-6DC36D50-D0A7-4DBC-BC89-9365BA2C1AA9Q47581193-3A43A6E4-87DC-499D-B285-D4A1D37BDE3FQ47815810-98C428A2-7369-4471-8303-E36CE5FA6DC7Q49314984-2DBBC873-880D-414B-A4BE-B5FC74ECC6E7Q49951911-4276CFEE-5CB9-4BE3-8FF4-88CDCEC9EAFFQ50020976-8EC345B0-809E-4AE7-8D60-77F4256E6834Q52640385-B1E3D8B2-19DF-42DB-9028-23C37B113EE6Q52668513-50D50508-7616-4D2F-94E9-61D553E073F8Q52813540-8321DA0E-58A6-41AA-9E50-C7F85CD0E2FEQ54191675-DC3F8F8D-53BF-4F9E-86B3-D79747BE03F9Q54980872-6B041108-97FD-4B2B-84C4-185D1AC9CB98Q55386134-0D3ADC5B-F1EA-4DB5-A551-76E647883257
P2860
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Indication and management of a ...... N international working group.
@en
type
label
Indication and management of a ...... N international working group.
@en
prefLabel
Indication and management of a ...... N international working group.
@en
P2093
P2860
P356
P1433
P1476
Indication and management of a ...... N international working group.
@en
P2093
A Bacigalupo
A M Vannucchi
A Rambaldi
C Harrison
D McLornan
D Niederwieser
D Rondelli
E Olavarria
F Cervantes
F Passamonti
P2860
P2888
P304
P356
10.1038/LEU.2015.233
P577
2015-08-21T00:00:00Z
P6179
1026597022